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Data from four randomized clinical trials trigger novel research concepts and 
may define new standards of care in newly diagnosed malignant gliomas: 
alkylating agent chemotherapy prolongs survival when added to radiotherapy 
for patients with anaplastic oligodendroglial tumors with 1p/19q codeletion 
over radiotherapy alone, and bevacizumab prolongs progression-free survival 
in patients with newly diagnosed glioblastoma. 
 
Anaplastic gliomas of World Health Organization (WHO) grade III and glioblastomas 
(WHO grade IV) are collectively referred to as malignant gliomas. The morphological 
subclassification of anaplastic gliomas into astrocytic, oligodendroglial or 
oligoastrocytic (mixed) is challenging and calling for molecular guidance, but has 
major prognostic significance. In contrast, the morphological subtyping of 
glioblastoma has no impact on clinical decision making. Maximal safe surgery as 
feasible followed by radiotherapy of the involved brain region had remained the 
standard of care for malignant gliomas for decades. The major advances in the 
diagnosis and management of malignant gliomas were the stepwise clarification of 
the prognostic versus predictive role of three molecular markers in malignant 
gliomas, 1p/19q co-deletion, O6-methylguanine DNA methyltransferase (MGMT) 
promoter methylation, and isocitrate dehydrogenase (IDH) 1 or 2 mutation, and the 
introduction of temozolomide (TMZ) chemoradiotherapy for newly diagnosed 
glioblastoma (TMZ/RT →TMZ).1 Moreover, recent high-throughput studies have 
further refined the molecular classification and somatic genomic landscape of 
glioblastoma.2,3 
 
In 2013, long-term follow-up of patients from two randomized clinical trials – 
European Organisation for Research and Treatment of Cancer (EORTC) 26951 and 
Radiation Therapy Oncology Group (RTOG) 9402 – demonstrated a major increase 
in median survival when procarbacine, lomustine (CCNU) and vincristine (PCV) were 
added to radiotherapy in patients with newly diagnosed anaplastic oligodendroglial 
tumors with 1p/19q co-deletions.4,5 That this difference in outcome between 
radiotherapy and combined modality treatment was not detected at the first report in 
2006 is best explained by the existence of two or more distinct subgroups of patients 
within the cohort of patients with 1p/19q-co-deleted tumors. Of note, subgroups of 
patients with as yet molecularly undefined tumors in the cohort with 1p/19q-intact 
tumors seem to benefit from combination therapy, too. Although these observations 
are largely exploratory and stem from clinical trials insufficiently powered to answer 
such questions, the similarities in outcome in two independent trials are remarkable 
and too relevant for patients even prior to prospective validation that they led to 
changes both in clinical practice and in the current transatlantic clinical trial portfolio: 
radiotherapy alone should no longer be considered standard of care in patients with 
1p/19q-co-deleted anaplastic oligodendroglial tumors; further, the radiotherapy alone 
arm of the CODEL trial (NCT00887146) was replaced by a radiotherapy plus PCV 
arm. Since PCV is more toxic than temozolomide and since it remains unclear to 
what extent radiotherapy contributed to the superior outcome in the experimental 
arms of the EORTC 26951 and RTOG 9402 trials or whether a similar outcome may 
have been achieved with chemotherapy alone, the revised CODEL trial shall now 
compare radiotherapy plus PCV versus TMZ/RT →TMZ versus TMZ alone. Long-
term follow-up data from NOA-04, the third relevant anaplastic glioma trial, which 
compared radiotherapy alone with chemotherapy alone, using TMZ or PCV,6 may 
soon indicate whether the hope for improved long-term control by alkylating agent 
chemotherapy alone is justified and help to validate the predictive biomarker, 1p/19q 
co-deletion. While the ongoing trials in anaplastic glioma are increasingly challenging 
because of demanding logistics and funding required for molecular profiling and long-
term follow-up, new insight derived from molecular studies constantly requires 
reconsideration of our clinical research strategies. Thus, we propose that, at least for 
clinical trials, the distinction between IDH-1/2-mutant and IDH-1/2-wildtype tumors 
should in the future override the distinction between WHO grade II, III and IV tumors 
and provide guidance for clinical practice as well as trial strategies (Figure).7 
 
The major debate in Neuro-Oncology in 2013 focused on the interpretation of 
outcome and the clinical impact of the AVAGlio and RTOG 0825 trials which explored 
the efficacy of bevacizumab, a monoclonal antibody targeting vascular endothelial 
growth factor (VEGF), in the treatment of newly diagnosed glioblastoma.8,9 Efficacy 
outcome parameters were similar: progression-free survival was prolonged by 3-4 
months whereas overall survival was not improved (Table). Due to differences in the 
statistical design, the gain in progression-free survival was significant in AVAGlio, but 
not in RTOG 0825. No particular subgroups defined by age, extent of resection or 
MGMT promoter methylation status with preferential benefit from bevacizumab were 
identified. A molecular signature predicting beneficial versus detrimental effects of 
bevacizumab on overall survival as proposed by RTOG requires validation. 
 
Safety and tolerability were overall comparable in both trials and provided no new 
signals, except contradictory observations on cognitive function and quality of life. 
AVAGlio reported decreased steroid use and preserved quality of life until 
progression with bevacizumab whereas RTOG 0825 reported decline in various 
domains of cognitive function and quality of life in bevacizumab-treated patients prior 
to progression. Although the test batteries were similar, the time points were not, and 
testing was enforced by the protocol in AVAGlio more than in RTOG 0825. Central 
review of neuroimaging in the AVAGlio trial appeared to rule out diffuse, non-
enhancing disease progression as a possible explanation for early cognitive decline 
in bevacizumab-treated patients. While the exploratory analysis of the (albeit) 
uncontrolled BRAIN trial of single agent bevacizumab in recurrent glioblastoma 
revealed improvement rather than decline in health-related quality of life and 
cognitive function,10 the possibility of adverse interactions between bevacizumab and 
radiotherapy remains. 
 
Because of the lack of a survival gain and the possibility that some patients may 
experience adverse effects on cognitive function and quality of life, the use of 
bevacizumab in newly diagnosed glioblastoma may be attractive particularly in 
patients with a low chance to benefit from standard radiochemotherapy, i.e., patients 
with large tumors lacking MGMT promoter methylation which also have a low 
likelihood to receive salvage therapies at progression. This includes a large 
proportion of the increasing population of elderly patients with glioblastoma. Of note, 
these clinically and molecularly defined subgroups of patients have been 
underrepresented in AVAGlio and more so in RTOG 0825. Meanwhile, controlled 
trials, like the EORTC 26101 trial (NCT01290939), are required to define the role for 
bevacizumab in recurrent glioblastoma. 
 
Moreover, biomarkers to predict primary resistance to VEGF inhibition and to identify 
the biochemical escape pathways from such treatments are urgently needed to better 
define the place, if any, of VEGF inhibitors in glioma treatment. After three competitor 
anti-angiogenic agents, enzastaurin, cediranib and cilengitide, have failed in 
glioblastoma, a final conclusion on whether AVAGlio and RTOG 0825 herald the end 
or the new beginning of the era of anti-angiogenic therapy for malignant glioma 
cannot be drawn. 
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Key advances 
 1p/19q testing should be done for all patients with oligodendroglial tumors.4-6 
 Anaplastic oligodendroglial tumors with 1p/19q co-deletions should no longer 
be treated with radiotherapy alone, but with alkylating agent chemotherapy, 
with or without radiotherapy.4-6 
 The introduction of molecular markers into the next WHO Classification of 
Tumors of the Nervous System is inevitable. 
 Bevacizumab prolongs progression-free, although not overall survival in newly 
diagnosed glioblastoma.8,9 
 Current controversies on clinical benefit versus safety and toxicity of 
bevacizumab require further, well-designed prospective clinical trials. 
 
Table 
 
 AVAGlio  RTOG 0825  
 Placebo 
n=463 
Bevacizumab 
n=458 
Placebo 
n=309 
Bevacizumab 
n=311 
PFS1 (months) 6.2 10.6 7.3 10.7 
 HR=0.64 (95% CI 0.55-0.74) HR=0.79 (95% CI 0.66-0.94) 
OS (months) 16.7 16.8 16.1 15.7 
 HR=0.88 (95% CI 0.76-1.02) HR=1.13 (95% CI 0.93-1.37) 
     
 
1by investigator 
 
 
Figure. IDH-driven approach to diffuse and malignant gliomas.1 
 
1Abbreviations: MGMT, O6-methyl-guanine DNA methylatransferase; MGMT+, 
hypermethylation of the promoter of the MGMT gene; MGMT-, no hypermethylation 
of the promoter of the MGMT gene; PCV, procarbazine, lomustine and vincristine; 
RT, radiotherapy; TMZ, temozolomide; WHO, World Health Organization 
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